Ertapenem controlled release - scPharmaceuticals

Drug Profile

Ertapenem controlled release - scPharmaceuticals

Latest Information Update: 07 Mar 2017

Price : $50

At a glance

  • Originator scPharmaceuticals
  • Class Amides; Antibacterials; Benzoic acids; Carbapenems; Pyrrolidines; Small molecules; Sulfides
  • Mechanism of Action Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Bacterial infections; Community-acquired pneumonia; Diabetic foot ulcer; Intra-abdominal infections; Skin and soft tissue infections; Urinary tract infections

Most Recent Events

  • 07 Mar 2017 Chemical structure information added
  • 01 Feb 2017 Clinical trials in Bacterial infections (SC)
  • 01 Feb 2017 Clinical trials in Community-acquired pneumonia (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top